Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to -$19.0 million.

  • Myriad Genetics' Change in Receivables fell 33170.73% to -$19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.6 million, marking a year-over-year decrease of 16608.7%. This contributed to the annual value of $8.7 million for FY2024, which is 3040.0% down from last year.
  • Myriad Genetics' Change in Receivables amounted to -$19.0 million in Q3 2025, which was down 33170.73% from $16.2 million recorded in Q2 2025.
  • Myriad Genetics' Change in Receivables' 5-year high stood at $17.5 million during Q1 2023, with a 5-year trough of -$19.0 million in Q3 2025.
  • For the 5-year period, Myriad Genetics' Change in Receivables averaged around $1.9 million, with its median value being $600000.0 (2024).
  • As far as peak fluctuations go, Myriad Genetics' Change in Receivables tumbled by 112000.0% in 2022, and later soared by 260000.0% in 2025.
  • Quarter analysis of 5 years shows Myriad Genetics' Change in Receivables stood at -$3.0 million in 2021, then grew by 16.67% to -$2.5 million in 2022, then soared by 52.0% to -$1.2 million in 2023, then plummeted by 233.33% to -$4.0 million in 2024, then crashed by 375.0% to -$19.0 million in 2025.
  • Its Change in Receivables was -$19.0 million in Q3 2025, compared to $16.2 million in Q2 2025 and -$800000.0 in Q1 2025.